Lewes, DE — (PRESS RELEASE JET) — 11/01/2017 — Mild Cognitive Impairment – Pipeline Review, H2 2017, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape.
Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety and apathy. Risk factors include diabetes, high blood pressure, and depression, smoking and elevated cholesterol.
Mild Cognitive Impairment – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 8, 6, 1, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 2 and 1 molecules, respectively.
Mild Cognitive Impairment (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Mild Cognitive Impairment (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Mild Cognitive Impairment (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Mild Cognitive Impairment (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Mild Cognitive Impairment (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Spanning over 113 pages “Mild Cognitive Impairment – Pipeline Review, H2 2017” report covers Introduction, Report Coverage, Mild Cognitive Impairment – Overview, Mild Cognitive Impairment – Therapeutics Development, Mild Cognitive Impairment – Therapeutics Assessment, Mild Cognitive Impairment – Companies Involved in Therapeutics Development, Mild Cognitive Impairment – Drug Profiles, Product Description, Mild Cognitive Impairment – Dormant Projects, Appendix. This report Covered Companies – AgeneBio Inc, Avraham Pharmaceuticals Ltd, CereSpir Inc, ConSynance Therapeutics Inc, Eisai Co Ltd, Eli Lilly and Company, Ensol Biosciences Inc, Genzyme Corp, IntelGenx Corp, Krenitsky Pharmaceuticals Inc, Merck & Co Inc, Nanotherapeutics Inc, Neuron Biopharma SA, Pfizer Inc, Sage Therapeutics Inc, SBI Pharmaceuticals Co Ltd, Suven Life Sciences Ltd, Takeda Pharmaceutical Company Ltd, Therapix Biosciences Ltd.
Please visit this link for more details: https://www.marketresearchreports.com/global-markets-direct/mild-cognitive-impairment-pipeline-review-h2-2017
Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) – Pipeline Review, H2 2017 – Visit at – https://www.marketresearchreports.com/global-markets-direct/glial-cell-line-derived-neurotrophic-factor-astrocyte-derived-trophic-factor-0
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) – Pipeline Review, H2 2017 – Visit at – https://www.marketresearchreports.com/global-markets-direct/growthdifferentiation-factor-8-myostatin-or-gdf8-or-mstn-pipeline-review-h2-0
About Market Research Reports, Inc.
Market Research Reports® Inc. is world’s largest store offering quality market research, SWOT analysis, competitive intelligence and industry reports. We help Fortune 500 to Start-Ups with the latest market research reports on global & regional markets which comprise key industries, leading market players, new products and latest industry analysis & trends.
Contact us for your market research requirements: http://www.marketresearchreports.com/contact
Powered by WPeMatico